The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. Learn more about NVSEF stock ...

CEO Katherine Stueland discusses company’s pivot to whole exome sequencing, whole genome sequencing tests for children with GEN Edge.

This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...

INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with ...

Unaudited results for the six months to 30 June 2024 VANCOUVER, BC / ACCESSWIRE / September 30, 2024 / Ondine Biomedical Inc.

Breast cancer is the second leading cause of cancer deaths in the U.S. and worldwide, pointing to the continuing need to improve treatment strategies and therapies that better patient survival and ...

UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating the ...

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...

Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.